Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
Hence, MiMedx Group's Capex-to-Operating-Income for the
three
months ended in Dec. 2023 was 0.02.
MiMedx Group Capex-to-Operating-Income Historical Data
The historical data trend for MiMedx Group's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MiMedx Group's Capex-to-Operating-Income
For the Biotechnology subindustry, MiMedx Group's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group's Capex-to-Operating-Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where MiMedx Group's Capex-to-Operating-Income falls into.
MiMedx Group Capex-to-Operating-Income Calculation
MiMedx Group's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group (NAS:MDXG) Capex-to-Operating-Income Explanation
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
MiMedx Group Capex-to-Operating-Income Related Terms
Thank you for viewing the detailed overview of MiMedx Group's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MDXG has been successfully added to your 